Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2019 - 03 - 11
点击次数: 0
Positions: CEO
Company: CanSino Biologics Inc.
个人简介:
宇学峰,康希诺生物股份公司联合创始人、执行董事及首席执行官。1981-1988年就读于南开大学生物系并获得硕士学位,1998年获得加拿大麦吉尔(McGill)大学微生物学博士学位。1996年在IBEX Technologies担任科学家,1998年加入赛诺菲巴斯德,2009年回国创办康希诺生物股份公司,在生物医药研究和开发方面有30多年的丰富经验。
发布时间: 2019 - 03 - 11
点击次数: 0
Positions: Chief Operation Officer
Company: CanSino Biologics Inc.
个人简介:
Shou Bai CHAO, became executive director on June 22, 2018 and Chief Operating Officer (COO)on May 1, 2018. He is deputy general manager of our company and is primarily responsible for the management of daily operations and strategy development. In addition, Dr. Chao also oversees production management and quality control. With nearly 33 years' experience in the biotechnology industry, he formerly served as Vice President and Senior Vice President at AstraZeneca plc from January 2008 to April 2018, and was president and the Board Director at the Chinese Biopharmaceutical Association-USA from June 2014 to June 2016.
发布时间: 2019 - 03 - 11
点击次数: 0
Positions: Professor of School of Basic Medical Sciences, Fudan University / Director of the National Engineering Lab for Therapeutic Vaccines
Company: Fudan University / National Engineering Lab for Therapeutic Vaccines
个人简介:
王宾,博士,教授,博士生导师, 美国辛辛那提大学医学院博士; 美国Wistar研究所博士后;曾任美国宾夕法尼亚大学医学院任助研和助教授、新疆大学特聘教授、中国农业大学特聘教授,现任复旦大学特聘教授、国际疫苗学会会员、美国免疫学会会员、国际DNA疫苗学会理事和美国GEN Advisory Board 委员、美国《DNA & Cell Biology》、《Human Vaccines & Immunotherapeutics》和中国《Virologica Sinica》、《Emerging Microbes & Infections 》《中华微生物学和免疫学杂志》和《微生物学报》等杂志的编委会委员。主要研究领域:治疗性疫苗和新型佐剂研究,免疫耐受机理等研究。自1995年以来,发表了140多篇SCI论文,获得了美国等各国发明专利35项、中国发明专利22项。完成一种新型佐剂的科研部级鉴定和农业部批准新型佐剂进入临床试验。完成一项人用治疗性疫苗佐剂临床研究和一项临床免疫学检测平台建立。完成两项农业部颁发的重组疫苗生物安全证书及生产评价证书。发明的免疫耐受疫苗技术,在全世界40多个国家申请注册,并完成了4项相关发明专利项目的技术转让。主持和参与了国家“863”重大项目、自然科学基金重点项目、传染病重大专项和新药创制专项等国家及省部级科研课题20多项。获得科学中国人2015年度人物奖和2项发明专利奖。
发布时间: 2019 - 03 - 11
点击次数: 0
Positions: Head of External R&D, Asia Pacific
Company: Sanofi Pasteur
个人简介:
Dr. Sean Du is the Regional Head of External R&D Asia-Pacific at Sanofi Pasteur. He is responsible to lead and manage the External R&D Asia-Pacific team in Beijing, evaluate scientific and technological development opportunities in Asia-Pacific region relevant to the business of Sanofi Pasteur, and support Sanofi Pasteur’s R&D Strategy in China. Sean has more than 14 years of scientific and business experience in the biotech and pharmaceutical industry. Before joining Sanofi Pasteur, Sean was Co-Founder and Chief Operating Officer at Atravax from May 2013 to September 2015 and Executive Director in Vaccine Research at Simcere Pharmaceutical Group from February 2010 to April 2013. Prior to Simcere, he worked as a Senior Scientist and Project Leader at Maxygen for more than 8 years. Sean has led preclinical development of multiple prophylactic and therapeutic vaccine candidates and achieved a Clinical Trial License from the China Food and Drug Administration (CFDA). Since 2010, Sean has led business development activities with academic institutions, biotech companies, and multinational pharmaceutical groups playing a lead role in the identification, evaluation, negotiation, and management of licensing opportunities. Sean received his Ph.D. degree in Biological Sciences from the University of Delaware, M.S degree in Microbiology from the Institute of Microbiology, Chinese Academy of Sciences, and B.S. degree in Microbiology from Shandong University. He received his postdoctoral training in molecular biology, biochemistry, and cell biology at Columbia University from 1998-2001.